Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : idb/to..idbe/nas long term growth -- Ignore unavailable to you. Want to Upgrade?

To: Dutch who wrote (17)	9/6/2000 12:28:18 PM
From: gg cox	Respond to of 85

To: Futurist who wrote (5193) From: Don Devlin Tuesday, Sep 5, 2000 7:17 PM ET Reply # of 5199 On December 6, 1996 I was the first person in Los Angeles to lease a GM Gen 1 EV1. In December of 1999 I leased a GM Gen 2 EV and am presently driving that car and averaging about 140 miles per charge (Nickel metal Hydride batteries made in Troy Michigan). Within a month or two after leasing the first EV1 I began to notice what appeared to be terrible advertising and absurd marketing. I made my feelings known to everyone involved and was assured that the advertising and marketing would change. Month after month the promises of change were given by GM and Saturn to the EV1 drivers but there were no changes. After a few more months and even years it became clear that this Giant Corporation and all other Auto companies were trying to sink the electric car. They had developed the egg that could kill the Golden Goose. How? No replaceable parts required, other than tires. No maintenance. Batteries (NiMH) that would last the life of the vehicle. In volume the EV could be sold for the amount of profit GM makes on their large SUVS. In 1998 I wrote the following letter to EVworld.co and it was published. Wolfgang Amadeus Mozart and the EV1 by Don Devlin Remember that very fine British play and movie, 'Amadeus'? The story dealt with Mozart's last years at a time when he was no longer the precocious child prodigy who had delighted the music world in 18th century Europe. He arrives at the king's court relatively unknown and is not immediately identified as the great genius who the world will later revere. There is one person however that does recognize the sublime brilliance of the great master. Salieri is the official composer of the Austrian court. Although Salieri is a minor composer, he is the most respected composer,and the very one who could do the most for Mozart and the very one in the court most threatened by Mozart's genius. Although conflicted by his great admiration for the young composer Salieri believes that for his own survival he must destroy the great artist who threatens his exalted position. And now we come to the General Motor's EV1. Is there an analogy here? GM and other automobile companies are experiencing one of their most profitable periods. Much of this affluence comes with the outsized SUVs that have now taken a bit more than half the consumer market. The profits on these monsters of waste and consumption and pollution are enormous. The parts replacement business is enormous. The infrastructure is in place. The General Motors EV1, the electric vehicle, is a masterpiece even in its first generation. The second generation is about to appear with very few significant changes but with the emphasis on greater range through the addition of advanced Nickel metal hydride batteries. The problem is that the EV1 is a snap to make and in volume could sell for a very reasonable price. There's no engine, no clutch, no transmission and on and on. The car is essentially an aerodynamic, electronic computer with wheels. It is a technological marvel. It has but one moving (Propulsion) part as opposed to hundreds in the Internal combustion engine. The EV1 is a no maintenance vehicle it could last more than ten years without ever setting wheels in a gas station or changing a part. No grease, no dirt, no smell, no pollution. That's not sometime in the future, that's now. The talk is that the new batteries will last the life of the vehicle, over 100,000 miles although that has not yet been officially announced. The EV1 is a powerhouse. It can power out of a dead stop faster than almost all Gas engine cars. With instant torque, it can feel like a G force if you hit the accelerator hard. It amazes everyone who has ever driven it. It is the most aerodynamic production vehicle in the world. It is beautiful and attracts the attention and approval of everyone who recognizes it. You may by now have heard reference to the famous 'EV smile' that comes from fellow drivers and the ever constant 'Thumbs up' EV drivers experience. The GM EV1 is simply the best URBAN , Suburban, and commuter vehicle in the world. Is it in the minds of the planners that they have created the machine that can kill their golden Goose? Some think that is the case and is the only thing that can explain what has to be the most unattractive most uninforming and in fact invisible advertising campaign in history. GM advertising has yet to show a full shot, or attractive picture of the car after two years in the marketplace. As an EV1 driver I can tell you that each day as I am charging at a public charger or simply, parked somewhere, a small crowd of people gather to ask questions about the car. They know not who makes it, how it is propelled, how far or fast it will go , where to go buy or lease it , how much does it cost, where do you charge it, will it run out of fuel and on and on. GM and all the other companies have told the potential consumers nothing at all that would induce them to buy or lease these vehicles. Is this incompetence or has Salieri decided the car must be destroyed? If this is intentional they are succeeding wonderfully in destroying or seriously delaying the advance of the electrics. If after two years, this is actually incompetence, the future of the electric vehicle is very much in doubt and so is the future of the executives responsible for this incredible debacle. I believe These thought have been proven to be true. September 5th 2000 Don Devlin

To: Dutch who wrote (17)	9/13/2000 6:29:31 PM
From: gg cox	Read Replies (1) \| Respond to of 85

geocities.com

To: Dutch who wrote (17)	12/14/2000 8:16:55 AM
From: capt rocky 1	Read Replies (2) \| Respond to of 85

Finance Home - Yahoo! - Help -------------------------------------------------------------------------------- in all the election bs. i overlooked this report. rocky( but i bought more at 4.37) [ Latest Headlines \| Market Overview \| News Alerts ] -------------------------------------------------------------------------------- Related Quotes IDB.TO IDBE 7.50 5 +0.00 +0 delayed 20 mins - disclaimer Monday November 27, 9:30 am Eastern Time Press Release SOURCE: ID Biomedical Corporation ID Biomedical Reports Third Quarter Results Company Anticipates Profitability for Y2000 VANCOUVER, Nov. 27 /PRNewswire/ - ID Biomedical Corporation (TSE: IDB, NASDAQ: IDBE) announced today its results for the quarter ending September 30, 2000. The net loss for the period was $1.5 million ($0.07 per share) as compared to a net loss of $5.3 million ($0.33 per share) for the same period last year. Revenue for the third quarter increased 233% over the comparable period in 1999. Revenue for the nine-month period ending September 30, 2000 increased 1,679% over the comparable period in 1999. << Three months Nine months ended September 30 ended September 30 -------------------------- 2000 1999 2000 1999 ---- ---- ---- ---- Total revenue $746,437 $223,857 $5,108,727 $287,224 Net loss $1,586,181 $1,401,852 $1,467,812 $5,260,742 Loss per share $0.06 $0.09 $0.07 $0.33 All dollar amounts are in Canadian dollars. >> As of November 1, 2000, the Company's cash balance was approximately $38 million. Commenting on the results, Todd R. Patrick, ID Biomedical's Chief Financial Officer said, ``This year has seen us substantially improve our cash flows from operations and our balance sheet metrics. With revenues already received, we can expect a profitable fourth quarter and project that our year- end results will show us earning no less than $0.12 per share. Our strong cash balance is a result of financing activities early in fiscal 2000 followed by more recent success in our genomics licensing program.'' ``While the revenues from our genomics business are very encouraging, we believe shareholders should remain focused on our vaccine portfolio as the major driver of future value'' said Dr. Anthony Holler, President of ID Biomedical. ``Our current balance sheet puts ID Biomedical in the position where realizing the goal of expanding our portfolio of clinical stage vaccines becomes readily achievable.'' ID Biomedical Corporation is a North American based biotechnology company focused on the development of a proprietary gene identification system, Cycling Probe(TM) Technology, for applications in genomics and diagnostics, and is also focused on the development of proprietary vaccine and immunotherapeutic products. Using Cycling Probe(TM) Technology, ID Biomedical is developing rapid tests that identify antibiotic resistant bacteria from culture. ID Biomedical is now licensing Cycling Probe(TM) Technology as well as its broad patents in signal amplification to the genomics and diagnostic industry for further product and technology development. Currently, Applied Biosystems (NYSE:PEB - news), Mitsubishi Chemical Corporation, Alexon-Trend, a subsidiary of Sybron International (NYSE:SYB - news), DiscoveRx, and Third Wave Technologies have obtained rights to IDB's patents. ID Biomedical is also developing vaccines for a number of different conditions. The Company's lead vaccine product for the prevention of diseases caused by group A streptococcus, StreptAvax(TM), is in a Phase I Clinical Trial sponsored and funded by the National Institute of Allergy and Infectious Diseases. Other vaccine products under development include: a vaccine for the prevention of tuberculosis which has been licensed to Aventis Pasteur, the vaccine subsidiary of Aventis S.A, a therapeutic vaccine for the prevention of AIDS and a vaccine for the prevention of disease caused by deadly strains of the E. coli bacteria. The foregoing information contains so-called forward-looking statements. These include statements about ID Biomedical's expectations, beliefs, intentions or strategies for the future, which it indicates by words or phrases such as ``anticipate'', ``expect'', ``intend'', ``plan'', ``will'', ``we believe'', ``ID Biomedical believes'', ``management believes'' and similar language. All forward-looking statements are based on ID Biomedical's current expectations and are subject to risks uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the ability to successfully complete preclinical and clinical development of its products; (ii) the ability to obtain and enforce timely patent and intellectual property protection for its technology and products; (iii) the ability to avoid, either by product design, licensing arrangement or otherwise, infringement of third parties' intellectual property; (iv) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of its products for human testing; (v) the ability to complete and maintain corporate alliances relating to the development and commercialization of its technology and products, (vi) market acceptance of its technology and products, and (vii) the competitive environment and impact of technological change. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them. ``Anthony F. Holler'' Anthony F. Holler President SOURCE: ID Biomedical Corporation Email this story - Most-emailed articles - Most-viewed articles -------------------------------------------------------------------------------- More Quotes and News: ID Biomedical Corp (Toronto:IDB.TO - news; NasdaqNM:IDBE - news) Related News Categories: biotech, earnings, medical/pharmaceutical -------------------------------------------------------------------------------- Help -------------------------------------------------------------------------------- Copyright © 2000 Yahoo! Inc. All rights reserved.Privacy Policy - Terms of Service Copyright 2000 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Questions or Comments?